Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

First results from the LUX dark matter experiment at the Sanford underground research facility.

Akerib DS, Ara├║jo HM, Bai X, Bailey AJ, Balajthy J, Bedikian S, Bernard E, Bernstein A, Bolozdynya A, Bradley A, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chapman JJ, Chiller AA, Chiller C, Clark K, Coffey T, Currie A, Curioni A, Dazeley S, de Viveiros L, Dobi A, Dobson J, Dragowsky EM, Druszkiewicz E, Edwards B, Faham CH, Fiorucci S, Flores C, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MG, Hall C, Hanhardt M, Hertel SA, Horn M, Huang DQ, Ihm M, Jacobsen RG, Kastens L, Kazkaz K, Knoche R, Kyre S, Lander R, Larsen NA, Lee C, Leonard DS, Lesko KT, Lindote A, Lopes MI, Lyashenko A, Malling DC, Mannino R, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad J, Morii M, Murphy AS, Nehrkorn C, Nelson H, Neves F, Nikkel JA, Ott RA, Pangilinan M, Parker PD, Pease EK, Pech K, Phelps P, Reichhart L, Shutt T, Silva C, Skulski W, Sofka CJ, Solovov VN, Sorensen P, Stiegler T, O'Sullivan K, Sumner TJ, Svoboda R, Sweany M, Szydagis M, Taylor D, Tennyson B, Tiedt DR, Tripathi M, Uvarov S, Verbus JR, Walsh N, Webb R, White JT, White D, Witherell MS, Wlasenko M, Wolfs FL, Woods M, Zhang C; LUX Collaboration.

Phys Rev Lett. 2014 Mar 7;112(9):091303. Epub 2014 Mar 4.

PMID:
24655239
2.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators.

Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators].

Supplemental Content

Loading ...
Support Center